Peter Svennilson Net Worth

The estimated Net Worth of Peter Svennilson is at least $189 millió dollars as of 26 April 2021. Mr. Svennilson owns over 76,410 units of Revolution Medicines Inc stock worth over $73,956,332 and over the last 9 years he sold RVMD stock worth over $115,245,713. In addition, he makes $0 as Independent Director at Revolution Medicines Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Svennilson RVMD stock SEC Form 4 insiders trading

Peter has made over 23 trades of the Revolution Medicines Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 76,410 units of RVMD stock worth $3,269,584 on 26 April 2021.

The largest trade he's ever made was buying 2,681,000 units of Revolution Medicines Inc stock on 27 October 2017 worth over $10,992,100. On average, Peter trades about 227,781 units every 45 days since 2016. As of 26 April 2021 he still owns at least 1,775,236 units of Revolution Medicines Inc stock.

You can see the complete history of Mr. Svennilson stock trades at the bottom of the page.

Peter Svennilson biography

Peter Svennilson serves as Independent Director of the Company. In February 2007, Mr. Svennilson founded The Column Group, a San Francisco-based biotechnology venture capital firm. He currently serves as its Managing Partner. In addition, Mr. Svennilson serves on the board of directors of ORIC Pharmaceuticals, a publicly traded biotechnology company, and Carmot Therapeutics, Ribon Therapeutics and Circle Pharma, all private biotechnology companies. Previously, he served as chairman of the board of directors of Seragon Pharmaceuticals, Inc. from January 2013 until it was acquired by Genentech in August 2014. He was also the chairman of the board of directors for Aragon Pharmaceuticals, Inc. from May 2009 until it was acquired by Johnson & Johnson in August 2013. Mr. Svennilson has also served as a member of the boards of directors of the following public biotechnology companies: NGM Biopharmaceuticals, Gritstone Oncology, Constellation Pharmaceuticals, Immune Design and PTC Therapeutics. Prior to founding The Column Group, he founded Three Crowns Capital, where he served as its Managing Partner from 1996 to 2007. Prior to founding Three Crowns Capital, from 1987 to 1993, he was an associate managing director in charge of European Investment Banking Origination at Nomura Securities in London. Mr. Svennilson is currently a trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received an M.B.A. from the Stockholm School of Economics and Finance.

What's Peter Svennilson's mailing address?

Peter's mailing address filed with the SEC is 1700 OWENS STREET, SUITE 500, SAN FRANCISCO, CA, 94158.

Insiders trading at Revolution Medicines Inc

Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder és Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.

What does Revolution Medicines Inc do?

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Complete history of Mr. Svennilson stock trades at Constellation Pharmaceuticals Inc, Gritstone Bio Inc, Ngm Biopharmaceuticals Inc, Revolution Medicines Inc, Oric Pharmaceuticals és RAPT Therapeutics

Revolution Medicines Inc executives and stock owners

Revolution Medicines Inc executives and other stock owners filed with the SEC include:

• Mark Goldsmith,
  Chairman of the Board, President, Chief Executive Officer
• Margaret Horn,
  Chief Operating Officer, General Counsel
• Steve Kelsey,
  President of Research and Development
• Dr. Mark A. Goldsmith Ph.D.,
  CEO, Pres & Chairman
• Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.,
  Pres of R&D
• Margaret A. Horn J.D.,
  COO, Gen. Counsel & Sec.
• Dr. Stephen M. Kelsey M.D., FRCP, FRC Path.,
  Pres of R&D
• Margaret A. Horn,
  COO, Gen. Counsel & Sec.
• Xiaolin Wang,
  Exec. VP of Clinical Devel.
• Dr. Mark A. Goldsmith M.D., Ph.D.,
  CEO, Pres & Chairman
• Alexis Borisy,
  Lead Independent Director
• Barbara Weber,
  Independent Director
• Vincent Miller,
  Independent Director
• Elizabeth Anderson,
  Independent Director
• Peter Svennilson,
  Independent Director
• Thilo Schroeder,
  Independent Director
• Eric Schmidt,
  Independent Director
• Neil Exter,
  Independent Director
• Jack Anders,
  Vice President - Finance and Principal Accounting Officer
• Dr. Martin D. Burke M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Jack Anders,
  Sr. VP of Fin. & Principal Accounting Officer
• Luan M. Wilfong,
  Sr. VP of HR
• Walter Reiher Ph.D.,
  Chief Information Officer
• David L. Pompliano,
  Founding Chief Scientific Officer
• Dr. Kevan M. Shokat,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Michael A. Fischbach,
  Academic Co-Founder & Member of Scientific Advisory Board
• Dr. Martin D. Burke,
  Co-Founder & Chairman of Scientific Advisory Board
• Frank Clyburn,
  
• Group Iii, Lpcolumn Group I...,
  
• Laurence Lasky,
  Director
• Group Iii, Lp Svennilson Pe...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iv, L.P.Third...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Lin Wei,
  Chief Medical Officer
• Jeff Cislini,
  General Counsel
• Stephen Michael Kelsey,
  See Remarks
• Rock Ventures Iii, L.P.Thir...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Xiaolin Wang,
  See Remarks
• Rock Ventures Ii, L.P.Third...,
  
• Rock Ventures Iii, L.P.Thir...,
  
• Sushil Patel,
  
• Flavia Borellini,
  
• Lorence H. Kim,